Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | NAMPT | P43490 | 1/20 | 0.36 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.36 |
| ▸ | OXTR | P30559 | 1/20 | 0.36 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.36 |
| ▸ | KRAS | P01116 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25409755 | 0.88 | GPR119 (0.42) | NR1H2EPHX2GPR119USP2SMN1; SMN2 | |
| SCHEMBL31104174 | 0.88 | NR1H2 (0.42) | NR1H2EPHX2GPR119USP2SMN1; SMN2 | |
| SCHEMBL18393607 | 0.86 | NR1H2 (0.56) | NR1H2EPHX2GPR119USP2SMN1; SMN2 | |
| SCHEMBL26401754 | 0.86 | NR1H2 (0.45) | NR1H2EPHX2GPR119USP2SMN1; SMN2 | |
| SCHEMBL25409047 | 0.85 | GPR119 (0.42) | NR1H2GPR119USP2SMN1; SMN2HPGD | |
| SCHEMBL21997549 | 0.84 | NR1H2 (0.44) | NR1H2EPHX2GPR119USP2SMN1; SMN2 | |
| SCHEMBL25413411 | 0.84 | NR1H2 (0.44) | NR1H2EPHX2GPR119USP2SMN1; SMN2 | |
| SCHEMBL18298972 | 0.83 | NR1H2 (0.43) | NR1H2EPHX2GPR119USP2SMN1; SMN2 | |
| SCHEMBL31104126 | 0.83 | NR1H2 (0.47) | NR1H2EPHX2GPR119USP2SMN1; SMN2 | |
| SCHEMBL25726515 | 0.83 | NR1H2 (0.43) | NR1H2EPHX2GPR119USP2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025226892-A1 | SPIROCYCLE-CONTAINING DIAMINOMETHYLENE PYRIMIDINE-2,4,6-TRIONE AGONISTS OF PARATHYROID HORMONE 1 AND INCRETIN RECEPTORS | SEPTERNA, INC. (US) | 2025-10-30 | — | — | WO | disclosed |
| CN-111944012-B | Aromatic amine targeting AR and BET protein degradation chimeric compound and application thereof | 海创药业股份有限公司 | 2023-08-29 | — | — | CN | disclosed |
| US-20220257774-A1 | AROMATIC AMINE AR AHD BET TARGETING PROTEIN DEGRADATION CHIMERA COMPOUND AND USE | HINOVA PHARMACEUTICALS INC. (CN) | 2022-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220257774-A1 | AROMATIC AMINE AR AHD BET TARGETING PROTEIN DEGRADATION CHIMERA COMPOUND AND USE | AR, BRD4, BRDT | NR1H2 687/4885EPHX2 2480/4885GPR119 762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.